Positive Initial Data from Phase 1/2 Trial of RTX-240 in Advanced Solid Tumors Demonstrated Single-Agent Activity Providing Initial Validation of the RED PLATFORM ®; Dose Optimization and Enrollment ...
CAMBRIDGE Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an ...
Markets Insider and Business Insider Editorial Teams were not involved in the creation of this post. Rubius Therapeutics NewsMORE Indices Commodities Currencies Stocks ...
The question of whether Rubius Therapeutics Inc. would disclose data with its cellular therapy, RTX-240, ahead of the American Association for Cancer Research (AACR) meeting next month was answered in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results